Psoriasis drug bimekizumab: new study looks at gene changes

NCT ID NCT06506916

Ongoing Disease control Sponsor: UCB Biopharma SRL Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jul 17, 2026 · Updated 2 times

Summary

This study tests the drug bimekizumab in 89 adults with moderate to severe plaque psoriasis, some of whom also have psoriatic arthritis. Researchers will measure changes in gene activity in skin samples after 48 weeks of treatment. The goal is to understand how the drug affects the body at a molecular level, not to cure the disease.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: bimekizumab (a biologic drug given as an injection)
What this could lead to: If successful, this study could show how bimekizumab works at the genetic level, potentially leading to better treatments for psoriasis and psoriatic arthritis.
What could go wrong: This is an exploratory study focused on gene markers, not on curing the disease. Results may not lead to new treatments, and side effects are possible with any biologic drug.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MODERATE TO SEVERE PLAQUE PSORIASIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

psoriasis psoriatic arthritis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MODERATE TO SEVERE PLAQUE PSORIASIS PSORIATIC ARTHRITIS

Contacts and locations

Locations

Ps0039 40072

Freiburg im Breisgau, Germany
Ps0039 40287

Frankfurt am Main, Germany
Ps0039 40347

Lodz, Poland
Ps0039 40515

Berlin, Germany
Ps0039 40625

Lodz, Poland
Ps0039 40757

Poznan, Poland
Ps0039 40761

Warsaw, Poland
Ps0039 40773

Wroclaw, Poland
Ps0039 50110

Ann Arbor, Michigan, 48109, United States
Ps0039 50140

Birmingham, Alabama, 35233, United States
Ps0039 50162

Fountain Valley, California, 92708, United States
Ps0039 50283

Tampa, Florida, 33613, United States
Ps0039 50491

Pittsburgh, Pennsylvania, 15213-2536, United States
Ps0039 50643

Rochester, New York, 14623, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.